| Latest Cel Sci News Headlines |
| Date | Time | Source | |
| 05/16/2008 | 1:00PM | PRNUS | CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
VIENNA, Va., May 16 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (AMEX:CVM) reports financial results for the three and six months ended March 31, 2008.
Geert Kersten, Chief Executive Officer of CEL-SCI Corporation said, "We are completely focused on getting our cancer therapy Multikine(R) into its pivotal Phase III... More...>> |
| 03/03/2008 | 11:00AM | PRNUS | CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities R
VIENNA, Va., March 3 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (AMEX:CVM) provided details today at its 2008 Annual Meeting of Shareholders on groundbreaking activities currently underway at its manufacturing facility near Baltimore, Maryland. The facility will be used to manufacture Multikine(R), the Company's... More...>> |
| 02/14/2008 | 4:15PM | PRNUS | CEL-SCI Corporation Reports First Quarter Financial Results
VIENNA, Va., Feb. 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (AMEX:CVM) reports financial results for the first quarter fiscal year 2008, ending December 31, 2007.
Highlights:
-- Net loss for the three months ending December 31, 2007 was
approximately $1.84 million compared with an operating loss... More...>> |
| 01/28/2008 | 9:25AM | PRNUS | CEL-SCI Corporation Releases Letter to Shareholders
VIENNA, Va., Jan. 28 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (AMEX:CVM) to its shareholders:
Dear Fellow Shareholders:
Our Company underwent a wonderful transformation last year from an intermediate stage company in its development to a late-stage biotechnology company... More...>> |
| 01/14/2008 | 9:00AM | PRNUS | CEL-SCI Corporation Announces 2007 Financial Results
VIENNA, Va., Jan. 14 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM) reports financial results for the fiscal year ending September 30, 2007.
CEL-SCI reports a net operating loss for fiscal year 2007 of $9,352,209 versus a net operating loss of $5,349,196 in fiscal year 2006. The loss per share for fiscal... More...>> |
| 11/09/2007 | 9:00AM | PRNUS | CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
VIENNA, Va., Nov. 9 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM) announced today that its Board of Directors has approved a Stockholder Rights Plan designed to ensure that all of its stockholders receive fair and equal treatment in the event of any proposal to acquire control of CEL-SCI.
Geert Kersten... More...>> |
| 10/31/2007 | 8:00AM | PRNUS | Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
NEW YORK, Oct. 31 /PRNewswire-FirstCall/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation (AMEX:CVM). The full 56-page report can be found at http://www.crystalra.com/.
CEL-SCI Corporation develops immune-based cancer and infectious... More...>> |
| 10/30/2007 | 9:00AM | PRNUS | CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
VIENNA, Va., Oct. 30 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the Rodman & Renshaw 9th Annual Healthcare Conference being held at the New York Plaza Hotel from November 5-7, 2007. The presentation will be focused on its Phase... More...>> |
| 10/29/2007 | 9:00AM | PRNUS | Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
VIENNA, Va., Oct. 29 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM) announced today that it has published a very comprehensive review of cancer immunotherapies on its new website. The link is located in the top right hand corner of its home page at http://www.cel-sci.com/ .
Geert Kersten, Chief Executive... More...>> |
| 10/18/2007 | 9:45AM | PRNUS | CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
VIENNA, Va., Oct. 18 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (AMEX:CVM) announced today that its Chief Executive Officer, Geert Kersten, is a featured presenter at the International Society for Pharmaceutical Engineering (ISPE) 2007 Chesapeake BioShowcase in Gaithersburg Maryland. Mr. Kersten will present on... More...>> |
| 09/19/2007 | 9:30AM | PRNUS | CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
VIENNA, Va., Sept. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM) announces that its CEL-1000 immunomodulator was shown to be able to jump start the immune response against the recombinant hepatitis B virus protein more quickly than did other vaccine adjuvants. This effect in the mouse model was seen within... More...>> |
| 09/17/2007 | 1:18PM | PRNUS | CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
VIENNA, Va., Sept. 17 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM) announces that its Chief Executive Officer, Geert Kersten, is a featured presenter at the Biotech/Pharma/Healthcare On-line Forum. The webcast presentation is scheduled for Tuesday, September 18, 2007 at 9:30 a.m. (Eastern Daylight Time... More...>> |
| 09/10/2007 | 9:45AM | PRNUS | CEL-SCI Corporation Releases Letter to Shareholders
VIENNA, Va., Sept. 10 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (AMEX:CVM) to its shareholders:
Dear Fellow Shareholders:
The past 12 months have been the most successful ever for CEL-SCI Corporation. The U.S. Food and Drug Administration (FDA) granted us the go- ahead... More...>> |
| 08/20/2007 | 9:15AM | PRNUS | CEL-SCI to Present at the Noble Financial Conference
VIENNA, Va., Aug. 20 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM), will present today at the Noble Financial Equity Conference in Charleston, South Carolina.
On August 20, 2007 at 3:30 pm E.D.T. Geert Kersten, Chief Executive Officer, will give a 25-minute presentation regarding CEL-SCI's late stage cancer... More...>> |
| 08/14/2007 | 9:35AM | PRNUS | CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
Biomedical Real Estate Group Backs Construction of Facility
VIENNA, Va., Aug. 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (AMEX:CVM) announced today that it has entered into an agreement with a biomedical real estate group under which CEL-SCI acquires long term use of a dedicated manufacturing facility for its... More...>> |
| 08/13/2007 | 5:45PM | PRNUS | CEL-SCI Corporation Reports Third Quarter 2007 Financial Results
VIENNA, Va., Aug. 13 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM) reports financial results for the three and nine months ending June 30, 2007.
The Company's net loss from operations for the quarter ended June 30, 2007 was $3,776,263 versus a net loss of $1,305,457 during the same quarter in 2006. The... More...>> |
| 06/13/2007 | 9:40AM | PRNUS | CEL-SCI Corporation Releases Letter to Shareholders
VIENNA, Va., June 13 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (AMEX:CVM) to its shareholders:
Dear Fellow Shareholders:
So far 2007 has been an excellent year for CEL-SCI and its cancer product Multikine(R). In January we received the US FDA go-ahead for the Phase III... More...>> |
| 06/12/2007 | 9:45AM | PRNUS | CEL-SCI Receives US FDA Orphan Drug Designation for Its Cancer Drug Multikine(R)
VIENNA, Va., June 12 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM) announced today that its cancer drug Multikine(R) has been granted orphan-drug designation as neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (head and neck cancer) by the United States Food and Drug Administration... More...>> |
| 05/29/2007 | 10:23AM | PRNUS | CEL-SCI CEO to Present at Dutton Associates' 'Recognizing Opportunity' SmallCap Conference in San Francisco May 30
VIENNA, Va., May 29 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM), a developer of cancer products, will present at Dutton Associates' "Recognizing Opportunity" SmallCap Conference. Geert Kersten, Chief Executive Officer, along with a select group of Dutton's top-followed companies, will update investment... More...>> |
| 05/23/2007 | 9:30AM | PRNUS | CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
VIENNA, Va., May 23 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (AMEX:CVM) announces that CEL-1000 increased the immune response against H5 avian influenza antigen in combination with MAS-1, a water-in-oil adjuvant delivery system. These findings were presented on May 23, 2007 by Dr. Daniel Zimmerman, Senior Vice... More...>> |